Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-13 4:55 pm Sale | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 0 0% | -1,492,771 (Position Closed) | View |
| 2024-02-13 4:48 pm Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | Affinity Asset Advisors LLC | 653,409 1.81% | 653,409 (New Position) | View |
| 2024-02-13 4:45 pm Sale | 13G | CONTEXT THERAPEUTICS INC CNTX | Affinity Asset Advisors LLC | 328,817 2.06% | -554,837 (-62.79%) | View |
| 2023-07-03 4:20 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Affinity Asset Advisors LLC | 7,477,000 9.23% | 7,477,000 (New Position) | View |
| 2023-02-13 4:11 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 1,492,771 7.04% | 357,406 (+31.48%) | View |
| 2022-05-09 5:11 pm Purchase | 13G | CONTEXT THERAPEUTICS INC CNTX | Affinity Asset Advisors LLC | 883,654 5.53% | 883,654 (New Position) | View |
| 2022-02-11 4:13 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 1,135,365 5.39% | 59,145 (+5.50%) | View |
| 2021-11-22 2:50 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 1,076,220 5.12% | 1,076,220 (New Position) | View |